- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
India to have 5 more COVID vaccines by Oct
These vaccines are Sputnik V vaccine, Johnson and Johnson vaccine, Novavax vaccine, Zydus Cadila's vaccine, and Bharat Biotech's Intranasal Vaccine.
New Delhi: As more and more states flag shortage of COVID-19 vaccine doses, the Central government has pressed the accelerator to scale up vaccine production manifold.
Top government sources told that by end of the third quarter of this year, India will be getting vaccines from five additional manufacturers. India currently manufactures Covishield and Covaxin.
Explaining the new strategy to manufacture additional vaccine doses, a source said "India currently has 2 COVID-19 vaccines being manufactured locally: Covishield and Covaxin, and we can expect five more vaccines by Q3 2021. These vaccines are Sputnik V vaccine (in collaboration with Dr. Reddy's), Johnson & Johnson vaccine (in collaboration with Biological E), Novavax vaccine (in collaboration with Serum India), Zydus Cadila's vaccine, and Bharat Biotech's Intranasal Vaccine. Safety and efficacy are the Union government's primary concerns while granting emergency use authorisation (EUA) to any COVID-19 vaccine in the country."
Out of almost 20 COVID-19 vaccines in various clinical and pre-clinical stages, Sputnik V vaccine will get the nod first. It is expected that Sputnik is likely to get the EUA within the next ten days.
Russian Direct Investment Fund (RDIF) has tied up with a host of Indian pharmaceutical players such as Hyderabad based Dr Reddy's Laboratories, Hetero Biopharma, Gland Pharma, Stelis Biopharma and Vichrow Biotech for the production of vaccine doses. With a production capacity of 850 million doses in the country, Sputnik V will provide a major shot in the arm in the fight against COVID-19.
When asked from a top-level source when will the vaccines be available for use, he said, "Sputnik is expected to be available latest by June, if all goes well Johnson and Johnson ( Bio E) will be available by August, Zydus Cadila will also be available by August, Novavax (Serum) by September and Nasal Vaccine (Bharat) by October."
The Government is making all efforts to accelerate the progress without cutting any corners in research, development, and clinical trial stages, the source added.
The government is taking all steps to augment vaccine production and availability in India. A decision has been taken at the highest level to ensure all steps are taken to help domestic manufacturers to scale up vaccine production manifold.
"The Government of India is determined to ensure India remains the pharmacy of the world and Indians have equitable access to the highest quality vaccines in the world. We encourage all COVID-19 vaccine manufacturers to come to India, as the Central Government is ready to provide manufacturing assistance, financial support, and partnership in running and designing clinical trials," sources added.
India is currently facing the second wave of COVID-19 pandemic with the number of new cases increasing each day.
coronavirus vaccinecovid-19coronaviruscovaxincovishieldjohnson and johnsonnovavaxzydus cadilabharat biotechsputnik vdr reddy's labs
Source : ANIRuchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story